MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Agenus ROE Ratio 2011-2026 | AGEN
Annual ROE Ratio Agenus
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 160.57 | 376.41 | -59.95 | 86.47 | 46.54 | 91.49 | 159.19 | 324.58 | -124.25 | -184.57 | 671.16 | 64.34 | 111.74 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 671.16 | -184.57 | 132.59 |
Quarterly ROE Ratio Agenus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.59 | 65.64 | 81.98 | 82.88 | 138.85 | 170.1 | 240.95 | 285.12 | 764.29 | 1187.49 | 730.82 | -64.86 | 433.77 | 453.23 | 847.08 | 558.95 | 576.79 | 103.52 | 94.37 | 89.11 | 84.96 | 80.14 | 79.47 | 49.5 | 64.14 | 63.16 | 54.76 | 93.96 | 111.84 | 140.88 | 168.1 | 159.19 | 179.74 | 235.36 | 265.91 | 324.57 | 235.74 | 112.98 | -16.53 | -124.25 | -215.04 | -231.72 | -209.52 | -184.58 | 57.21 | 255.78 | 539.38 | 671.15 | 573.14 | 442.35 | 233.03 | 64.35 | 62.33 | 56.35 | 44.65 | 111.74 | 26.57 | 27.64 | 28.63 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1187.49 | -231.72 | 196.18 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
30.78 | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 3.53 | -3.54 % | $ 116 M | France |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
2477.67 | - | -19.68 % | $ 18.4 M | Canada |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
-20.19 | $ 0.79 | -1.15 % | $ 4.31 M | China |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
China SXT Pharmaceuticals
SXTC
|
-21.4 | $ 2.01 | -1.36 % | $ 2.86 M | China |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-46.04 | $ 0.67 | 7.08 % | $ 624 K |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-4.59 | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-531.22 | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-116.29 | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
18.68 | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
149.7 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.69 | -0.74 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |